1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Hikal Limited
  6. News
  7. Summary
    524735   INE475B01022

HIKAL LIMITED

(524735)
  Report
End-of-day quote Bombay Stock Exchange  -  05-26
382.00 INR   +1.03%
04/23Hikal Limited Announces Closure of Manufacturing Unit Located at MIDC Taloja, Dist. Raigad, Within 15 Days
CI
02/23HIKAL LIMITED : Ex-dividend day for interim dividend
FA
02/18TRANSCRIPT : Hikal Limited, Q3 2022 Earnings Call, Feb 18, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hikal Results Presentation FY22Q2

10/26/2021 | 10:56am EDT

Results Presentation - Q2 & H1 FY22

Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Hikal Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

© Hikal Limited

Executive Chairman's Message

"Hikal has delivered another quarter of positive performance. From a segmental performance perspective, the Crop

Protection business has performed well, registering a positive YoY growth of 105% in Q2 on the back of strong volume

growth of our existing products and further scale up of volumes of our new products. We expect this positive

momentum to continue in the next few quarters based on a healthy pipeline of products at various stages.

Unusually heavy rainfalls in the Raigad region had a severe impact on our Mahad operations leading to the

shutdown of our Mahad facility for several weeks. This led to a loss in sales and profitability for the crop division.

Relentless efforts by our teams from all our sites helped in restarting our operations in a staggered manner and we

were able to return to normal operations in due course.

Our Pharmaceutical business remained flat due to a slower offtake by customers in this quarter. This was primarily

due to several raw material shortages and global logistics issues. We expect raw material challenges to continue in

Jai Hiremath

the next few months and are working with both our suppliers and customers to mitigate the price fluctuations.

Our capex plans and our new product launch plans remain intact for both our divisions. We are seeing tailwinds in

terms of new opportunities arising from global supply chain disruptions and the China plus one strategy playing out.

Global supply chain challenges coupled with a steep increase in input raw material prices continue to pose a

challenge for our industry going forward. We have put in significant efforts over the past few years on developing

alternate sourcing partners and backward integration of certain raw materials. While this will help us in the long-

term, we do expect certain disruptions in the short term. Over the next several months we expect the situation to

normalise.

As part of our efforts to fight the Pandemic, our employees across the company are 100% vaccinated for their first

dose and about 75% have been vaccinated for their second dose. We expect to have all our employees fully

vaccinated by the year end.

In alignment with our long-term vision and bold aspirations, we have set out on a transformational journey with a Global consultant to create a roadmap across our business verticals. This initiative will drive future growth and profitability, by giving us a new strategic direction and enabling us to chart our progress in a sustainable manner. The journey forward will not just entail accelerating growth in our existing pharma and crop protection businesses but

will also see strong growth in our emerging business verticals such as animal health and biocides.

© Hikal Limited

Quarterly Financial Highlights

Financial Highlights - Q2 FY22

Revenue - Q2 FY22

EBITDA - Q2 FY22

EBITDA Margin - Q2 FY22

Rs. 469 Crore

Rs. 91 Crore

19.4%

YoY

QoQ

YoY

QoQ

YoY

QoQ

26%

3%

30%

-5%

62 bps

-158 bps

PAT - Q2 FY22

EPS - Q2 FY22

Rs 3.54

Rs. 44 Crore

YoY

QoQ

YoY

QoQ

63%

-13%

63%

-13%

© Hikal Limited

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Hikal Limited published this content on 26 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 October 2021 14:55:08 UTC.


© Publicnow 2021
All news about HIKAL LIMITED
04/23Hikal Limited Announces Closure of Manufacturing Unit Located at MIDC Taloja, Dist. Rai..
CI
02/23HIKAL LIMITED : Ex-dividend day for interim dividend
FA
02/18TRANSCRIPT : Hikal Limited, Q3 2022 Earnings Call, Feb 18, 2022
CI
02/17Hikal to Challenge Plant Closure Order Issued by Maharashtra Pollution Control Body
MT
02/14HIKAL : Results Presentation FY22Q3
PU
02/14HIKAL : Results FY22Q3
PU
02/14Hikal Limited Declares Interim Dividend for the Financial Year 2021-22, Payable on or B..
CI
02/14Hikal Limited Reports Earnings Results for the Third Quarter and Nine Months Ended Dece..
CI
2021ICRA Raises Hikal's Rating to A+; Lowers Outlook to Stable
MT
2021HIKAL : Related Party Transactions on a consolidated basis for the half year ended 30th Se..
PU
More news
Financials
Sales 2022 19 426 M 250 M 250 M
Net income 2022 1 907 M 24,6 M 24,6 M
Net Debt 2022 - - -
P/E ratio 2022 24,7x
Yield 2022 0,41%
Capitalization 47 101 M 607 M 607 M
Capi. / Sales 2022 2,42x
Capi. / Sales 2023 2,13x
Nbr of Employees -
Free-Float 31,0%
Chart HIKAL LIMITED
Duration : Period :
Hikal Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HIKAL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 382,00 INR
Average target price 533,67 INR
Spread / Average Target 39,7%
EPS Revisions
Managers and Directors
Sameer Jai Hiremath Managing Director & Director
Kuldeep Jain Chief Financial Officer
Jai Vishwanath Hiremath Executive Chairman
Rajasekhar Reddy Secretary & Compliance Officer
Kannan Kadankote Unni Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HIKAL LIMITED-27.47%600
JOHNSON & JOHNSON5.86%472 231
PFIZER, INC.-8.70%302 932
ROCHE HOLDING AG-12.16%282 336
ELI LILLY AND COMPANY17.11%282 164
ABBVIE INC.10.78%266 074